Symbols

BNGO

Bionano Genomics·NASDAQ

--(--)

BNGO fundamentals

BNGO Q4 2025 Earnings

Bionano Genomics (BNGO) released its earnings on Mar 23, 2026: revenue was 7.95M (YoY -2.60%), beat estimates; EPS was -2.475 (YoY +79.60%), met estimates.

Revenue / YoY

7.95M

-2.60%

EPS / YoY

-2.475

+79.60%

Report date

Mar 23, 2026

BNGO Earnings Call Summary for Q4,2025

Strategic Shift Success: Routine use customers drive 83% of consumables revenue, with 60 validated sites averaging $131,000/year.
Profitability Improvement: Non-GAAP gross margin expanded to 47% (vs. 35% in 2024), operating expenses reduced 47% to $36.6 million.
Reimbursement Catalyst: Hematologic malignancy CPT code pricing increased 47% to $1,853.22, supporting 2026 growth.
Operational Scale: Radboud University Medical Center processing 3,000 OGM samples/year, demonstrating academic adoption at scale.
2026 Outlook: $30-33 million revenue target (+5-16%), driven by reimbursement expansion and existing customer utilization.

Earnings

EPS

Revenue

Revenue & Expenses

BNGO has released its 2025 Q4 earnings report, with revenue of 7.95M, reflecting a YoY change of -2.60%, and net profit of -7.93M, showing a YoY change of 60.58%. The Sankey diagram below clearly presents BNGO's revenue sources and cost distribution.

Key Indicators

Bionano Genomics (BNGO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Bionano Genomics (BNGO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Bionano Genomics (BNGO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Bionano Genomics (BNGO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown